Scientific article

Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique

Published inRevue médicale suisse, vol. 4, no. 175, p. 2203-2204,2206-7
Publication date2008

Long acting beta2-agonists (LABA) are one of the most widely prescribed anti-asthmatic therapies. Nevertheless, their chronic utilization has been associated in large clinical studies with severe asthma exacerbations and asthma-related deaths raising concern about their safety. Awaiting further evidence to definitely identify susceptible subgroups, LABA should be used with caution. Inhaled corticosteroids (ICS) is the preferred asthma controller option and LABA should be used only in association with ICS in patients insufficiently controlled under ICS therapy.

  • Adrenal Cortex Hormones/therapeutic use
  • Adrenergic beta-Agonists/therapeutic use
  • Asthma/drug therapy
  • Clinical Trials as Topic
  • Humans
Citation (ISO format)
MARTI, Christophe, JANSSENS, Jean-Paul, RUTSCHMANN, Olivier Thierry. Place des bêta-agonistes de longue durée dans le traitement de l’asthme bronchique. In: Revue médicale suisse, 2008, vol. 4, n° 175, p. 2203–2204,2206–7.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation12/09/2013 5:33:00 PM
First validation12/09/2013 5:33:00 PM
Update time03/14/2023 8:55:21 PM
Status update03/14/2023 8:55:21 PM
Last indexation01/16/2024 2:05:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack